Arbutus Biopharma Corp (ABUS) Institutional Ownership

Ownership Summary

A total of 167 institutions have reported a stake in Arbutus Biopharma Corp (NASDAQ:ABUS) as of September 2025, according to recent 13F filings with the SEC.

• These investors collectively held 61.9% of the company's total shares outstanding in September 2025, up from 61.6% in June 2025.
• In percentage terms, this reflects as a holdings change of 1.35% quarter on quarter, and an increase of 16.78% year over year.
• Among the 167 institutional holders of Arbutus Biopharma, 68 added to their stakes while 59 trimmed their positions and 40 held steady.
• Collectively, institutional investors increased their stake in Arbutus Biopharma to 118.71Mn shares as of September 2025, a change that is up by 1.58Mn shares quarter on quarter and up 16.37Mn shares year over year.
• MORGAN STANLEY continues to be the largest institutional holder of Arbutus Biopharma as of September 30, 2025, with a position of 24.45Mn shares, representing 12.75% of the company's outstanding stock.
• Among the most significant buyers of Arbutus Biopharma during September 2025 were ADAGE CAPITAL PARTNERS GP, L.L.C. (2.44Mn), UBS Group AG (584.39K), Two Seas Capital LP (547.94K), DIADEMA PARTNERS LP (516.30K), Western Standard LLC (507.85K).
• Leading sellers of Arbutus Biopharma stock in September 2025 included GOLDMAN SACHS GROUP INC (866.35K), BlackBarn Capital Partners LP (603.52K), Saba Capital Management, L.P. (581.36K), FOURSIXTHREE CAPITAL LP (578.39K), STATE STREET CORP (361.44K).
• The top 10 institutional holders of Arbutus Biopharma for the quarter ending September 2025 included MORGAN STANLEY (24.45Mn), Whitefort Capital Management, LP (13.34Mn), BlackRock, Inc. (12.68Mn), Two Seas Capital LP (10.99Mn), VANGUARD GROUP INC (8.99Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.01Mn), STATE STREET CORP (4.10Mn), GEODE CAPITAL MANAGEMENT, LLC (3.67Mn), ADAR1 Capital Management, LLC (2.90Mn), GOLDMAN SACHS GROUP INC (2.17Mn).